LISA Post Market Clinical Follow-Up Study: Documentation of Clinical Outcomes After Surgery With LISA Implant

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBACKBONE

About this trial

The study is a post-market surveillance study of the Lumbar Implant for Stiffness Augmentation (LISA), a medical device, which is used to treat low-back pain that accompanies degenerative lesions of grades II, III, and IV (Pfirrmann MRI classification). "Post-market" means the device (i.e. the LISA implant) being used in this study has already obtained CE certification and is commercially available for use in the European market.

The LISA device consists of 3 components: A PEEK interspinous spacer, a polyester band, and a titanium blocker. The spacer is positioned between two adjacent spinous processes, the band is belted around the spinous processes and through the spacer, and the blocker is used to lock the band inside the spacer.

Medical Device manufacturers conduct "post-market" clinical studies in order to continuously evaluate the product scientifically and to comply with legal and ethical obligations. With these studies, the long-term safety as well as performance of their medical devices are assessed.

This study, which is initiated and sponsored by BACKBONE (LISA designer, developer, manufacturer and marketer), aims to evaluate the long-term safety and performance of the LISA implant for the treatment of lumbar degenerative disease and to evaluate the treatment.

Eligibility criteria

Qualifiers

Skeletally mature patients Patient ≥18 years of age

Patients with low-back pain caused by degenerative lesions of grade II, III and IV (Pfirrmann MRI classification)

Failed conservative treatment for low back pain conducted for at least 6 months

Disqualifiers

Stage V degenerative disk lesions in Pfirrmann's MRI classification

Spondylolisthesis

Osteoporosis

Non-specific back pain

Trial design

Treatments tested in this trial

  • Lumbar Implant for Stiffness Augmentation (LISA)

Treatment groups

136 Participants
are divided into 1 treatment group

Sponsors and collaborators